Please use this identifier to cite or link to this item: https://doi.org/10.1080/14737167.2023.2295474
DC FieldValue
dc.titleCost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore
dc.contributor.authorElaine Hsuen Lim
dc.contributor.authorAndrew Lim
dc.contributor.authorJasmeet Singh Khara
dc.contributor.authorJohn Cheong
dc.contributor.authorJek Fong
dc.contributor.authorSivabalan Sivanesan
dc.contributor.authorMatt Griffiths
dc.contributor.authorEmma New
dc.contributor.authorSoo-chin Lee
dc.date.accessioned2024-03-18T03:10:56Z
dc.date.available2024-03-18T03:10:56Z
dc.date.issued2024-01-30
dc.identifier.citationElaine Hsuen Lim, Andrew Lim, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Matt Griffiths, Emma New, Soo-chin Lee (2024-01-30). Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research 24 (3) : 413-426. ScholarBank@NUS Repository. https://doi.org/10.1080/14737167.2023.2295474
dc.identifier.issn1473-7167
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/247511
dc.publisherTaylor & Francis
dc.sourceTaylor & Francis
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1080/14737167.2023.2295474
dc.description.sourcetitleExpert Review of Pharmacoeconomics & Outcomes Research
dc.description.volume24
dc.description.issue3
dc.description.page413-426
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10.108014737167.2023.2295474.zip2.19 MBZIP

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.